| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.078 | 0.05 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.06 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.076 | 0.06 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.06 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |